Review of current knowledge on HPV vaccination: An Appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening

Journal of Clinical Virology

Volumn 38, Issue 3, 2007, Pages 189-197

  Arbyn, Marc ^a,b,d   Dillner, Joakim ^c,d  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c European Union   (Belgium)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Cervical cancer; Guideline; HPV; Vaccine

Indexed keywords

3 O DESACYL 4' PHOSPHORYL LIPID A; ALUMINIUM HYDROXYPHOSPHATE SULFATE; ALUMINUM HYDROXIDE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; CANCER SCREENING; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; INFECTION RISK; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SEXUAL BEHAVIOR; SYSTEMATIC REVIEW; TH1 CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS PARTICLE;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CHILD; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES; UTERINE CERVICAL NEOPLASMS;

EID: 33847013679     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.12.009     Document Type: Review

References (70)

1. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 (2006) 1-9
2. Bosch F.X., Lorincz A.T., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
3. Carter J.J., Koutsky L.A., Wipf G.C., Christensen N.D., Lee S.K., Kuypers J., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174 (1996) 927-936
4. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181 (2000) 1911-1919
5. Christensen N.D., Kreider J.W., Kan N.C., and DiAngelo S.L. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181 (1991) 572-579
6. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., and El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 6 (2005) 204
7. Cohen J. Public health. High hopes and dilemmas for a cervical cancer vaccine. Science 308 (2005) 618-621
8. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 9 (1999) 423-430
9. Dillner J., Kallings I., Brihmer C., Sikstrom B., Koskela P., Lehtinen M., et al. Seropositivity to human papillomavirus types 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J Infect Dis 173 (1996) 1394-1398
10. Dillner J., Lehtinen M., Bjorge T., Luostarinen T., Youngman L., Jellum E., et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 89 (1997) 1293-1299
11. Dubin G., Colau B., Zahaf T., Quint W., Martin M., and Jenkins D. Cross-protection against persistent hpv infection, abnormal cytology and CIN associated with HPV-16 AND 18 related HPV types by a HPV 16/18 L1 virus-like particle vaccine. Vancouver (2005)
12. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN. 2004.Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, Version 2.0; IARCPress, Lyon, 2004.
13. Franco E.L., and Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23 (2005) 2388-2394
14. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4 (2004) 46-55
15. Galloway D.A. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 3 (2003) 469-475
16. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191 Suppl 1 (2005) S97-S106
17. Garnett G.P., Kim J.J., French K., and Goldie S.J. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 (2006) 178-186
18. Geipert N. Vaccinating men for HPV: new strategy for preventing cervical cancer in women?. J Natl Cancer Inst 97 (2005) 630-631
19. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
20. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 (2004) 604-615
21. Greenstone H.L., and Nieland J.D. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95 (1998) 1800-1805
22. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
23. Harper D.M., et al. Sustained efficacy up to 4-5 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
24. Hines J.F., Ghim S.J., Christensen N.D., Kreider J.W., Barnes W.A., Schlegel R., et al. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol Oncol 55 (1994) 13-20
25. Ho G.Y., Studentsov Y.Y., Bierman R., and Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prevent 13 (2004) 110-116
26. Hughes J.P., Garnett G.P., and Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13 (2002) 631-639
27. IARC Monograph Working Group, et al. IARC monographs on the evaluation of carcinogenic risks to humans, vol 90: human papillomavirusses. Lyon: International Agency for Research in Cancer; 2007, in press.
28. Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., and Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73 (1999) 6188-6190
29. Kirnbauer R., Hubbert N.L., Wheeler C.M., Becker T.M., Lowy D.R., and Schiller J.T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86 (1994) 494-499
30. Konya J., and Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 82 (2001) 205-238
31. Koutsky L.A., Holmes K.K., Critchlow C.W., Stevens C.E., Paavonen J., Beckmann A.M., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327 (1992) 1272-1278
32. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
33. Lacey C.J., Lowndes C.M., and Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 (2006) 35-41
34. Lehtinen M. Vaccination against human papillomaviruses shows great promise. The Lancet 364 (2004) 1731-1732
35. Lehtinen M. Preparations for implementing human papillomavirus vaccination should begin. Eur Surveill 10 (2005) 1-2
36. Lehtinen M., Luukkaala T., Wallin K.L., Paavonen J., Thoresen S., Dillner J., et al. Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol 22 (2001) 117-124
37. Lehtinen M., Apter D., Dubin G., Kosunen E., Isaksson R., Korpivaara E.L., et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 17 (2006) 517-521
38. Lehtinen M., Idanpaan-Heikkila I., Lunnas T., Palmroth J., Barr E., Cacciatore R., et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 17 (2006) 237-246
39. Lowy D.R., and Frazer I.H. Chapter 16: prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr (2003) 111-116
40. Man S. Human cellular immune responses against human papillomaviruses in cervical neoplasia. Expert Rev Mol Med 1998 (1998) 1-19
41. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 (2006) 18-27
42. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
43. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
44. Munoz N., Castellsague X., de Gonzalez A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24 (2006) 1-10
45. Niedergang F., Didierlaurent A., Kraehenbuhl J.P., and Sirard J.C. Dendritic cells: the host Achille's heel for mucosal pathogens?. Trends Microbiol 12 (2004) 79-88
46. Nieland J.D., and Da Silva D.M. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 73 (1999) 145-152
47. Orth G., and Favre M. Human papillomaviruses. Biochemical and biologic properties. Clin Dermatol 3 (1985) 27-42
48. Pagliusi S.R., and Teresa A.M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23 (2004) 569-578
49. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S11-S25
50. Roden R.B., Hubbert N.L., Kirnbauer R., Christensen N.D., Lowy D.R., and Schiller J.T. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 70 (1996) 3298-3301
51. Roden R.B., Yutzy W.H., Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270 (2000) 254-257
52. Schiller J.T., and Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2 (2004) 343-347
53. Schiller J.T., and Nardelli-Haefliger D. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine 24 (2006) 147-153
54. Schneider A., and Gissmann L. Cervical cancer. The potential role of human papillomavirus (HPV)-specific vaccines in prevention and treatment. Am J Cancer 2 (2003) 1-253
55. Shah K.V., Viscidi R.P., Alberg A.J., Helzlsouer K.J., and Comstock G.W. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prevent 6 (1997) 233-237
56. Skjeldestad FE. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk, 43rd Annual Meeting of IDSA, San Francisco; 2005.
57. Stanley M.A. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Exp Rev Vaccines 2 (2003) 381-389
58. Steenbergen R.D., de Wilde J., Wilting S.M., Brink A.A., Snijders P.J., and Meijer C.J. HPV-mediated transformation of the anogenital tract. J Clin Virol 32 Suppl 1 (2005) S25-S33
59. Stern P.L. Recent developments in human papillomavirus vaccines. Exp Opin Invest Drugs 13 (2004) 959-971
60. Stern P.L. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 32 Suppl 1 (2005) S72-S81
61. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 (2004) 1915-1923
62. Tjalma W.A., Arbyn M., Paavonen J., Van Waes T.R., and Bogers J.J. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int J Gynecol Cancer 14 (2004) 751-761
63. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., et al. Prohylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
64. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
65. Viscidi R.P., Schiffman M.A., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prevent 13 (2004) 324-327
66. White W.I., Wilson S.D., Palmer-Hill F.J., Woods R.M., Ghim S.J., Hewitt L.A., et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73 (1999) 4882-4889
67. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. J Epidemiol 157 (2003) 218-226
68. Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 (2001) 1831-1836
69. Zhou J., Sun X.J., Stenzel D.J., and Frazer I.H. Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 (1991) 251-257
70. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 (2002) 342-350